Perspective Therapeutics (CATX) Competitors $4.67 -1.50 (-24.31%) (As of 09:04 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CATX vs. ESTA, BLFS, AORT, PLSE, BVS, CBLL, EYE, FNA, LQDA, and AVNSShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Establishment Labs (ESTA), BioLife Solutions (BLFS), Artivion (AORT), Pulse Biosciences (PLSE), Bioventus (BVS), CeriBell (CBLL), National Vision (EYE), Paragon 28 (FNA), Liquidia (LQDA), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Establishment Labs BioLife Solutions Artivion Pulse Biosciences Bioventus CeriBell National Vision Paragon 28 Liquidia Avanos Medical Establishment Labs (NASDAQ:ESTA) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment. Does the media favor ESTA or CATX? In the previous week, Perspective Therapeutics had 7 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for Perspective Therapeutics and 2 mentions for Establishment Labs. Perspective Therapeutics' average media sentiment score of 0.78 beat Establishment Labs' score of 0.56 indicating that Perspective Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Perspective Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ESTA or CATX? Establishment Labs received 101 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Perspective Therapeutics an outperform vote while only 61.70% of users gave Establishment Labs an outperform vote. CompanyUnderperformOutperformEstablishment LabsOutperform Votes11661.70% Underperform Votes7238.30% Perspective TherapeuticsOutperform Votes15100.00% Underperform VotesNo Votes Is ESTA or CATX more profitable? Establishment Labs has a net margin of -46.13% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Establishment Labs' return on equity.Company Net Margins Return on Equity Return on Assets Establishment Labs-46.13% -184.55% -24.81% Perspective Therapeutics -4,096.66%-27.40%-23.16% Do insiders and institutionals hold more shares of ESTA or CATX? 72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, ESTA or CATX? Perspective Therapeutics has lower revenue, but higher earnings than Establishment Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstablishment Labs$165.15M7.09-$78.50M-$2.58-16.21Perspective Therapeutics$1.43M220.73-$46.51MN/AN/A Which has more volatility and risk, ESTA or CATX? Establishment Labs has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Do analysts recommend ESTA or CATX? Establishment Labs presently has a consensus target price of $60.60, indicating a potential upside of 44.94%. Perspective Therapeutics has a consensus target price of $21.57, indicating a potential upside of 361.91%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than Establishment Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Establishment Labs 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Perspective Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPerspective Therapeutics beats Establishment Labs on 11 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$458.24M$4.47B$5.07B$19.96BDividend YieldN/A36.79%4.99%3.49%P/E RatioN/A12.2983.5735.39Price / Sales291.1644.861,220.3018.01Price / CashN/A52.2739.4621.27Price / Book1.275.766.934.58Net Income-$46.51M$13.76M$119.12M$985.93M7 Day Performance-30.94%-1.08%-1.83%0.45%1 Month Performance-51.69%0.58%-3.64%1.05%1 Year PerformanceN/A50.91%31.64%24.67% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics2.7597 of 5 stars$4.67-24.3%$21.57+361.9%N/A$315.65M$1.43M0.00116Analyst RevisionESTAEstablishment Labs2.1311 of 5 stars$41.81+11.4%$60.60+44.9%+90.0%$1.17B$165.15M0.00960High Trading VolumeBLFSBioLife Solutions0.8729 of 5 stars$25.01+11.5%$27.50+10.0%+86.5%$1.16B$143.27M0.00409Analyst ForecastInsider TradeAnalyst RevisionAORTArtivion1.9824 of 5 stars$27.16+0.9%$31.00+14.1%+92.4%$1.14B$354M-1,358.001,500Positive NewsPLSEPulse Biosciences1.5374 of 5 stars$16.14-5.3%N/A+157.8%$992.93M$700,000.000.00140Positive NewsBVSBioventus2.7241 of 5 stars$11.41-1.6%$13.00+13.9%+195.6%$925.92M$512.34M29.721,200Positive NewsCBLLCeriBellN/A$25.83+3.1%$31.20+20.8%N/A$925.23MN/A0.00N/AQuiet Period ExpirationAnalyst RevisionGap UpEYENational Vision3.0614 of 5 stars$11.34+0.5%$14.00+23.5%-42.1%$893.03M$2.13B-56.7013,998Positive NewsFNAParagon 282.1583 of 5 stars$10.35-1.4%$15.60+50.7%-0.3%$866.50M$216.39M-13.99343,000Analyst RevisionLQDALiquidia3.7431 of 5 stars$10.12-0.4%$24.00+137.2%+55.7%$856.56M$17.49M-6.2150Analyst RevisionAVNSAvanos Medical3.9871 of 5 stars$17.87+0.4%N/A-16.6%$821.31M$673.30M52.563,771Positive News Related Companies and Tools Related Companies ESTA Alternatives BLFS Alternatives AORT Alternatives PLSE Alternatives BVS Alternatives CBLL Alternatives EYE Alternatives FNA Alternatives LQDA Alternatives AVNS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CATX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
